Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy

被引：0
|
作者：
Hiroki Ishihara
Toshio Takagi
Tsunenori Kondo
Hidekazu Tachibana
Kazuhiko Yoshida
Kenji Omae
Junpei Iizuka
Hirohito Kobayashi
Kazunari Tanabe
机构：
[1] Tokyo Women’s Medical University,Department of Urology, Kidney Center
[2] Tokyo Women’s Medical University Medical Center East,Department of Urology
[3] Kyoto University Graduate School of Medicine/School of Public Health,Department of Healthcare Epidemiology
[4] Fukushima Medical University,Center for Innovative Research for Communities and Clinical Excellence
来源：
International Journal of Clinical Oncology | 2018年 / 23卷
关键词：
Renal cell carcinoma; Targeted therapy; Third-line therapy; Tyrosine kinase inhibitor; mTORi; Metastasis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：559 / 567
页数：8
相关论文
共 50 条
  • [1] Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy
    Ishihara, Hiroki
    Takagi, Toshio
    Kondo, Tsunenori
    Tachibana, Hidekazu
    Yoshida, Kazuhiko
    Omae, Kenji
    Iizuka, Junpei
    Kobayashi, Hirohito
    Tanabe, Kazunari
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (03) : 559 - 567
  • [2] Time to progression after first-line tyrosine kinase inhibitor predicts survival in patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy
    Ishihara, Hiroki
    Kondo, Tsunenori
    Yoshida, Kazuhiko
    Omae, Kenji
    Takagi, Toshio
    Iizuka, Junpei
    Tanabe, Kazunari
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (09) : 542.e1 - 542.e9
  • [3] Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI
    Kwonoh Park
    Jae-Lyun Lee
    Inkeun Park
    Seongjoon Park
    Yongcheol Ahn
    Jin-Hee Ahn
    Shin Ahn
    Cheryn Song
    Jun Hyuk Hong
    Choung-Soo Kim
    Hanjong Ahn
    [J]. Medical Oncology, 2012, 29 : 3291 - 3297
  • [4] Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI
    Park, Kwonoh
    Lee, Jae-Lyun
    Park, Inkeun
    Park, Seongjoon
    Ahn, Yongcheol
    Ahn, Jin-Hee
    Ahn, Shin
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    [J]. MEDICAL ONCOLOGY, 2012, 29 (05) : 3291 - 3297
  • [5] Evaluation of second-line response to targeted therapy following progression on first-line cediranib, an oral pan-vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), in advanced renal cell carcinoma (RCC).
    Richter, S.
    Gan, H. K.
    MacKenzie, M. J.
    Hotte, S. J.
    Mukherjee, S. D.
    Kollmannsberger, C. K.
    Ivy, S. P.
    Fernandes, K.
    Halford, R.
    Massey, C.
    Wang, L.
    Moore, M. J.
    Sridhar, S. S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor
    Sacre, Anne
    Barthelemy, Philippe
    Korenbaum, Clement
    Burgy, Mickael
    Wolter, Pascal
    Dumez, Herlinde
    Lerut, Evelyne
    Loyson, Tine
    Joniau, Steven
    Oyen, Raymond
    Debruyne, Philip R.
    Schoffski, Patrick
    Beuselinck, Benoit
    [J]. ACTA ONCOLOGICA, 2016, 55 (03) : 329 - 340
  • [7] Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy
    Kawano, Yoshiaki
    Takahashi, Wataru
    Eto, Masatoshi
    Kamba, Tomomi
    Miyake, Hideaki
    Fujisawa, Masato
    Kamai, Takao
    Uemura, Hirotsugu
    Tsukamoto, Taiji
    Azuma, Haruhito
    Matsubara, Akio
    Nishimura, Kazuo
    Nakamura, Tsuyoshi
    Ogawa, Osamu
    Naito, Seiji
    [J]. CANCER SCIENCE, 2016, 107 (07) : 1013 - 1017
  • [8] First-line Treatment Result Influence Second-line Regimen Selection in Targeted Therapy for Metastatic Renal Cell Carcinoma
    Li, Jian-Ri
    Yang, Cheng-Kuang
    Wang, Shian-Shiang
    Chen, Chuan-Shu
    Chiu, Kun-Yuan
    Cheng, Chen-Li
    Yang, Chi-Rei
    Ho, Hao-Chung
    Ko, Jiunn-Liang
    Ou, Yen-Chuan
    [J]. ANTICANCER RESEARCH, 2014, 34 (10) : 5643 - 5647
  • [9] Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy
    Felip, E.
    Gridelli, C.
    Baas, P.
    Rosell, R.
    Stahel, R.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (07) : 1507 - 1519
  • [10] Third-line Therapy for metastatic Renal cell carcinoma
    Rexer, H.
    [J]. ONKOLOGE, 2011, 17 (12): : 1161 - 1162
12345